Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial
Open Access
- 10 January 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Abstract
We conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. The primary endpoint was safety. Secondary endpoints were objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), 1-year survival probability, and sitravatinib pharmacokinetics. Sitravatinib dose of 35 mg daily plus nivolumab 3 mg/kg and ipilimumab 1 mg/kg resulted in high frequency of immune-related adverse events. Subsequent dose reduction of ipilimumab to 0.7 mg/kg allowed safe escalation of sitravatinib up to 100 mg daily. Overall, the triplet combination achieved ORR 45.5%, DCR 86.4%, median PFS 14.5 months, and 1-year survival 80.8%. Median OS and DOR were not reached. Sitravatinib exposure increased dose-dependently. Single-cell RNA-seq of longitudinally collected tumor biopsies from 12 patients identified a tumor cell-specific epithelial-mesenchymal transition-like program associated with treatment resistance and poor outcomes. Treatment resistance was characterized by a transition from cytotoxic to exhausted T cell state and enrichment for M2-like myeloid cells. The observed hypothesis-generating changes in gene expression dynamics and cellular states may help inform future strategies to optimize immunotherapy efficacy. Clinical Trials.gov identifier: NCT04518046Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA288448)
- U.S. Department of War (KC200096P1)
This publication has 52 references indexed in Scilit:
- Systemic Therapy for Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2017
- Massively parallel digital transcriptional profiling of single cellsNature Communications, 2017
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 TherapyCell, 2016
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcomaOncotarget, 2015
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor OriginClinical Cancer Research, 2013
- Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced MelanomaClinical Cancer Research, 2013
- Vessel co‐option in primary human tumors and metastases: an obstacle to effective anti‐angiogenic treatment?Cancer Medicine, 2013
- Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMPBlood, 2008
- Monitoring late-onset toxicities in phase I trials using predicted risksBiostatistics, 2007